Mostrar el registro sencillo del ítem

Progression-free survival on endocrine therapy, before or after chemotherapy, in hormone receptor-positive HER2-negative metastatic breast cancer

dc.rights.licenseopenen_US
dc.contributor.authorCORBAUX, Pauline
dc.contributor.authorLARDY-CLEAUD, Audrey
dc.contributor.authorALEXANDRE, Marie
dc.contributor.authorFONTANILLES, Maxime
dc.contributor.authorLEVY, Christelle
dc.contributor.authorVIANSONE, Alessandro Adriano
dc.contributor.authorMAILLIEZ, Audrey
dc.contributor.authorDEBLED, Marc
dc.contributor.authorGONCALVES, Anthony
dc.contributor.authorLE DU, Fanny
dc.contributor.authorLEREBOURS, Florence
dc.contributor.authorFERRERO, Jean Marc
dc.contributor.authorEYMARD, Jean Christophe
dc.contributor.authorMOURET-REYNIER, Marie Ange
dc.contributor.authorPETIT, Thierry
dc.contributor.authorFRENEL, Jean Sebastien
dc.contributor.authorDALENC, Florence
hal.structure.identifierBordeaux population health [BPH]
dc.contributor.authorCOURTINARD, Coralie
dc.contributor.authorCHAIX, Marie
dc.contributor.authorBACHELOT, Thomas
dc.date.accessioned2021-12-07T08:52:12Z
dc.date.available2021-12-07T08:52:12Z
dc.date.issued2021-10-23
dc.identifier.issn1573-7217 (Electronic) 0167-6806 (Linking)en_US
dc.identifier.urihttps://oskar-bordeaux.fr/handle/20.500.12278/124013
dc.description.abstractEnPURPOSE: A major question when treating HR+/HER2- metastatic breast cancer (MBC) is whether early introduction of chemotherapy (CT) increases endocrine resistance. We aimed to describe progression-free survival (PFS) under first endocrine therapy (ET) depending on whether given before or after CT in a large nationwide cohort, in the pre-CDK era. METHODS: The real-life retrospective ESME database includes all patients with MBC whose first-line treatment was initiated between 2008 and 2014 in one of the 18 French Comprehensive Cancer Centres. Our primary objective was to compare PFS from start of first ET in patients with HR+/HER2- MBC who received ET or CT first. RESULTS: We identified 6293 patients who received at least one ET line during their first two therapeutic lines for MBC. As first-line therapy, 3832 (60.9%) received ET alone (ET1 1st group), whilst 2461 (39.1%) received CT, including 2024 patients (32.2%) with maintenance ET after CT (ET1 after CT group). Median PFS under first ET was 12.4 months (95% CI 11.9-13.1) in ET 1st group vs. 12.6 months in ET1 after CT group (95% CI 12.1-13.4), HR 0.96 (95% CI 0.90-1.01, P = 0.1277). CONCLUSIONS: PFS under first ET appears identical whether prescribed before or after chemotherapy. These data suggest chemotherapy does not promote endocrine resistance.
dc.language.isoENen_US
dc.subject.enAdvanced breast cancer
dc.subject.enHR+/HER2−
dc.subject.enEndocrine therapy
dc.subject.enChemotherapy
dc.subject.enProgression-free survival
dc.subject.enReal-word data
dc.title.enProgression-free survival on endocrine therapy, before or after chemotherapy, in hormone receptor-positive HER2-negative metastatic breast cancer
dc.typeArticle de revueen_US
dc.identifier.doi10.1007/s10549-021-06382-6en_US
dc.subject.halSciences du Vivant [q-bio]/Santé publique et épidémiologieen_US
dc.identifier.pubmed34687411en_US
bordeaux.journalBreast Cancer Research and Treatmenten_US
bordeaux.hal.laboratoriesBordeaux Population Health Research Center (BPH) - UMR 1219en_US
bordeaux.institutionUniversité de Bordeauxen_US
bordeaux.institutionINSERMen_US
bordeaux.teamEPICENE_BPH
bordeaux.peerReviewedouien_US
bordeaux.inpressnonen_US
hal.identifierhal-03468337
hal.version1
hal.date.transferred2021-12-07T08:52:15Z
hal.exporttrue
dc.rights.ccPas de Licence CCen_US
bordeaux.COinSctx_ver=Z39.88-2004&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.jtitle=Breast%20Cancer%20Research%20and%20Treatment&rft.date=2021-10-23&rft.eissn=1573-7217%20(Electronic)%200167-6806%20(Linking)&rft.issn=1573-7217%20(Electronic)%200167-6806%20(Linking)&rft.au=CORBAUX,%20Pauline&LARDY-CLEAUD,%20Audrey&ALEXANDRE,%20Marie&FONTANILLES,%20Maxime&LEVY,%20Christelle&rft.genre=article


Archivos en el ítem

ArchivosTamañoFormatoVer

No hay archivos asociados a este ítem.

Este ítem aparece en la(s) siguiente(s) colección(ones)

Mostrar el registro sencillo del ítem